How AOD 9604 Works at the Molecular Level The lipolytic activity of growth hormone has been understood since the 1960s
The compound sits at a low evidence tier there is a reasonable preclinical base and some early human data suggesting a fat-loss signal, but that is a very different thing from established clinical efficacy
HHS has announced that GHK-Cu is expected to return to Category 1, which would restore compounding access for injectable formulations. BPC-157 On 23 July 2026, PCAC voted to recommend adding BPC-157 to the 503A Bulks List, against FDA staff, who had recommended against listing
Consequently, it is preferred by many of the medical directors with whom we work as a means of providing metabolic assistance without causing the traditional side effects such as heart palpitations and jitters seen with stimulants containing caffeine, (e.g., sympathomimetic drugs)
Oral and sublingual GHK-CU dosing Oral delivery offers convenience without injections